CXCL13 variant predicts pegylated‐interferon α treatment response in HBeAg‐positive chronic hepatitis B patients

Abstract As a key immune cytokine, C‐X‐C motif chemokine ligand 13 (CXCL13) has been reported to play critical roles in immune control of hepatitis B virus (HBV) infection. We aimed to screen single‐nucleotide polymorphisms (SNPs) of CXCL13 for predicting response to pegylated interferon‐alpha (PegIFNα) therapy of chronic hepatitis B (CHB) patients. Two independent cohorts with a total of 945 (Cohort 1, n = 238; Cohort 2, n = 707) hepatitis B e antigen (HBeAg)‐positive CHB patients treated with PegIFNα were enrolled in this retrospective cohort study. Eight candidate SNPs were selected through gene‐wide SNP mining within or flanking CXCL13 . A polygenic score (PGS) was utilized to assess the cumulative effects of multiple SNPs. The associations of candidate SNPs and PGS with combined response (CR, defined as the combination of HBeAg seroconversion and HBV DNA level <3.3log 10 IU/mL) and hepatitis B surface antigen (HBsAg) level were evaluated. Among the eight candidate SNPs, rs76084459 which is located at upstream of CXC L13 was significantly associated with both CR ( p = 0.002) and HBsAg level ( p = 0.015). A PGS integrating CXCL13 _rs76084459 and five other SNPs, which were previously identified as predictors of PegIFNα treatment response, was further strongly correlated with CR ( p = 1.759 × 10 −10 ) and HBsAg level ( p = 0.004). This study demonstrated that CXCL13 _rs76084459 can predict response to PegIFNα treatment of HBeAg‐positive CHB patients. A PGS composed of six SNPs including CXCL13 _rs76084459 predicts PegIFNα treatment response better.